Assessing responses to treatment of opportunistic mycoses and salvage strategies

Current Infectious Disease Reports

Volumn 13, Issue 6, 2011, Pages 492-503

  Wirk, Baldeep ^a   Wingard, John R ^a  

^a UNIVERSITY OF FLORIDA COLLEGE OF MEDICINE   (United States)

Author keywords

Antifungal response assessment; Antifungal therapy; Invasive fungal disease; Opportunistic mycoses; Salvage strategies

Indexed keywords

AMPHOTERICIN B; AMPHOTERICIN B DEOXYCHOLATE; AMPHOTERICIN B LIPID COMPLEX; ANTIFUNGAL AGENT; CASPOFUNGIN; DNA; ECHINOCANDIN; FLUCONAZOLE; FLUCYTOSINE; FLUORODEOXYGLUCOSE F 18; GALACTOMANNAN; ITRACONAZOLE; LAMIVUDINE; MICAFUNGIN; NEVIRAPINE; POSACONAZOLE; STAVUDINE; VORICONAZOLE;

ARTICLE; CANDIDEMIA; CRYPTOCOCCAL MENINGITIS; DISEASE ASSOCIATION; DISEASE MARKER; DRUG EFFICACY; DRUG ELIMINATION; DRUG HALF LIFE; DRUG MEGADOSE; DRUG SUBSTITUTION; DRUG TOLERABILITY; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; ENZYME IMMUNOASSAY; FEBRILE NEUTROPENIA; FUNGUS GROWTH; HUMAN; INFECTION CONTROL; INFECTION RESISTANCE; INFECTION RISK; INVASIVE ASPERGILLOSIS; INVASIVE CANDIDIASIS; MAINTENANCE DRUG DOSE; MUCORMYCOSIS; NEPHROTOXICITY; NONHUMAN; OPPORTUNISTIC INFECTION; POLYMERASE CHAIN REACTION; POSITRON EMISSION TOMOGRAPHY; SALVAGE THERAPY; SURVIVAL TIME; SYSTEMIC MYCOSIS; TREATMENT DURATION; TREATMENT RESPONSE; UNSPECIFIED SIDE EFFECT;

EID: 81155139680     PISSN: 15233847     EISSN: 15343146     Source Type: Journal    
DOI: 10.1007/s11908-011-0217-5     Document Type: Article

References (57)

1. B De Pauw TJ Walsh PJ Donnelly, et al. 2008 Revised definitions of invasive fungal disease from the European Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Disease Mycoses Study Group (EORTC/MSG) Consensus Group Clin Infect Dis 46 1813 1821 18462102 10.1086/588660 This article updates definitions of IFD
2. BH Segal R Herbrecht DA Stevens, et al. 2008 Defining responses to therapy and study outcomes in clinical trials of invasive fungal diseases: Mycoses Study Group and European Organization for Research and Treatment of Cancer consensus criteria Clin Infect Dis 47 674 683 18637757 10.1086/590566 This article standardizes definitions of responses to antifungal therapies
3. JR Wingard P Ribaud HT Schlamm R Herbrecht 2008 Changes in death overtime after treatment for invasive aspergillosis Cancer 12 2309 2312 10.1002/cncr.23441 Elegant study outlining invasive aspergillosis attributable mortality criteria (Pubitemid 351628643)
4. PG Papas CMF Rotstein RF Betts, et al. 2007 Micafungin versus caspfungin for treatment of candidemia and other forms of invasive candidiasis Clin Infect Dis 45 883 893 10.1086/520980 (Pubitemid 47580382)
5. ER Kuse P Chetchotisakd CA da Cunha, et al. 2007 Micafungin versus liposomal amphotericin B for candidemia and invasive candidosis: a phase III randomized double-blind trial Lancet 369 1519 1527 17482982 10.1016/S0140- 6736(07)60605-9 1:CAS:528:DC%2BD2sXkvFGmt7c%3D (Pubitemid 46670281)
6. DL Horn L Ostrosky-Zeichner MI Morris, et al. 2010 Factors related to survival and treatment success in invasive candidiasis or candidemia: a pooled analysis of two large, prospective, micafungin trials Eur J Clin Microbiol Infect Dis 29 223 229 20013016 10.1007/s10096-009-0843-0 1:STN:280: DC%2BC3c%2FktFOisg%3D%3D
7. M Nucci E Anaissie RF Betts, et al. 2010 Early removal of central venous catheter in patients with candidemia does not improve outcome: analysis of 842 patients from 2 randomized clinical trials Clin Infect Dis 51 295 303 20578829 10.1086/653935
8. EP Brass JE Edwards 2010 Should the guidelines for management of central venous catheters in patients with candidemia be changed now? Clin Infect Dis 51 304 306 20578828 10.1086/653936
9. M Nucci JR Perfect 2008 When primary antifungal therapy fails Clin Infect Dis 46 1426 1433 18419447 10.1086/587101 (Pubitemid 351589944)
10. JR Wingard 2008 Learning from our failures: the antifungal treatment conundrum Clin Infect Dis 46 1434 1435 18419448 10.1086/587102 (Pubitemid 351589945)
11. EJ Anaissie 2007 Trial design for mold-active agents: time to break the mold-aspergillosis in neutropenic adults Clin Infect Dis 44 1298 1306 17443466 10.1086/514352 1:STN:280:DC%2BD2s3jsVWntA%3D%3D (Pubitemid 46717291)
12. D Caillot JF Couaillier A Bernard, et al. 2001 Increasing volume and changing characteristics of invasive pulmonary aspergillosis on sequential thoracic computed tomographic scans in patients with neutropenia J Clin Oncol 19 253 259 11134220 1:STN:280:DC%2BD38%2Fls1Sqtw%3D%3D (Pubitemid 32063503)
13. MH Miceli J Maertens K Buve, et al. 2007 Immune reconstitution inflammatory syndrome in cancer patients with pulmonary aspergillosis recovering from neutropenia: proof of principle, description, and clinical and research implications Cancer 110 112 120 17525971 10.1002/cncr.22738 This article defines IRIS which can confound interpretation of radiological findings (Pubitemid 46986424)
14. L Pagano M Caira A Candoni, et al. 2010 Invasive aspergillosis in patients with acute myeloid leukemia: A SEIFEM-2008 registry study Haematologica 95 644 650 19850903 10.3324/haematol.2009.012054
15. S Ascioglu JH Rex B de Pauw, et al. 2002 Defining opportunisitic invasive fungal infections in immunocompromised patients with cancer and hematopoietic stem cell transplants: an international consensus. Invasive Fungal Infections Cooperative Group of the European Organization for Research and Treatment of Cancer; Mycoses Study Group of the National Institutes of Allergy and Infectious Diseases Clin Infect Dis 34 7 14 11731939 10.1086/323335 1:STN:280: DC%2BD3MnosVOltg%3D%3D (Pubitemid 33152659)
16. S Reuter W Kern C Zenz, et al. 2009 Prognostic factors for invasive aspergilosis in patients with haematological malignancies Scand J Infect Dis 41 483 490 19347772 10.1080/00365540902856529
17. R Herbrecht J Maertens L Baila, et al. 2010 Caspofungin first-line therapy for invasive aspergillosis in allogeneic hematopoietic stem cell transplant patients: an European Organisation for Research and Treatment of Cancer study Bone Marrow Transplant 45 1227 1233 20062093 10.1038/bmt.2009.334 1:CAS:528:DC%2BC3cXosVGgtLY%3D
18. R Herbrecht DW Denning TF Patterson, et al. 2002 Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis New Engl J Med 347 08 415 10.1056/NEJMoa020191 (Pubitemid 34851833)
19. O Cornely J Maertens M Bresnik, et al. 2007 Liposomal amphotericin B as initial therapy for invasive mold infection: a randomized trial comparing a high-loading dose regimen with standard dosing (AmBiLoad trial) Clin Infect Dis 44 1289 1297 17443465 10.1086/514341 1:CAS:528:DC%2BD2sXmtFegtro%3D (Pubitemid 46717290)
20. DW Denning 2007 Comparison of 2 studies of treatment of invasive aspergillosis Clin Infect Dis 45 1106 1108 17879935 10.1086/521942 (Pubitemid 47580366)
21. OA Cornely J Maertens AJ Ullmann, et al. 2007 Reply to Denning Clin Infect Dis 45 1108 1110 10.1086/521943 (Pubitemid 47580367)
22. N Singh JM Aguado H Bonatti, et al. 2009 Zygomycosis in solid organ transplant recipients: a prospective, matched case-control study to assess risk for disease and outcome J Infect Dis 200 1002 1011 19659439 10.1086/605445
23. AE Brouwer A Rajanuwong W Chierakul, et al. 2004 Combination antifungal therapies for HIV-associated crytpococcal meningitis: a randomized trial Lancet 363 1764 1767 15172774 10.1016/S0140-6736(04)16301-0 1:CAS:528: DC%2BD2cXksVanu7s%3D (Pubitemid 38698379)
24. T Bicanic C Muzoora A Brouwer, et al. 2009 Independent association between rate of clearance of infection and outcome of HIV-associated cryptococcal meningitis: analysis of a combined cohort of 262 patients Clin Infect Dis 49 702 709 19613840 10.1086/604716 1:CAS:528:DC%2BD1MXhtFOju7bP
25. JC Nussbaum A Jackson D Namiarika, et al. 2010 Combination flucytosine and high-dose fluconazole compared with fluconazole monotherapy for the treatment of cryptococcal meningitis: a randomized trial from Malawi Clin Infect Dis 50 338 344 20038244 10.1086/649861 1:CAS:528:DC%2BC3cXislSqtrc%3D
26. SA Shelbourne 3rd J Darcourt AC White Jr, et al. 2005 The role of immune reconstitution inflammatory syndrome in AIDS-related Cryptococcus neoformans disease in the era of highly active antiretroviral therapy Clin Infect Dis 40 1049 1052 10.1086/428618 (Pubitemid 40418316)
27. JW Hiemenz II Raad JA Maertens, et al. 2010 Efficacy of caspofungin as salvage therapy for invasive aspergillosis compared to standard therapy in a historical cohort Eur J Clin Microbiol Infect Dis 29 1387 1394 20703506 10.1007/s10096-010-1013-0 1:CAS:528:DC%2BC3cXhtlehtr7K
28. D Caillot V Latrabe A Thiebaut, et al. 2010 Computed tomography in pulmonary invasive aspergillosis in hematological patients with neutropenia: a useful tool for diagnosis and assessment of outcomes in clinical trials Eur J Radiol 74 e172 e175 19577873 10.1016/j.ejrad.2009.05.058 Outlines evolution of radiological changes of IPA with antifungal therapy
29. D Caillot A Thiebaut R Herbrecht, et al. 2007 Liposomal amphotericin B in combination with caspofungin for invasive aspergillosis in patients with hematological malignancies: a randomized pilot study (Combistrat Trial) Cancer 110 2740 2746 17941026 10.1002/cncr.23109 1:CAS:528:DC%2BD1cXitVOgsw%3D%3D Outlines evolution of radiological changes of IPA with antifungal therapy (Pubitemid 350250344)
30. NG Almyroudis DP Kontoyiannis KA Sepkowitz, et al. 2006 Issues related to the design and interpretation of clinical trials of salvage therapy for invasive mold infection Clin Infect Dis 43 1449 1455 17083020 10.1086/508455 (Pubitemid 44845648)
31. AK Agarwal PD Rogers SR Baerson, et al. 2003 Genome wide expression profiling of the response to polyene, pyrimidine, azole and echinocandin antifungal agents in Saccharomyces cerevisiae J Biol Chem 278 34998 35015 12824174 10.1074/jbc.M306291200 1:CAS:528:DC%2BD3sXntVWqtrk%3D (Pubitemid 37102261)
32. T Mahfouz E Anaissie 2003 Prevention of fungal infections in the immunocompromised host Curr Opin Investig Drugs 4 974 990 14508882 1:CAS:528:DC%2BD3sXnslyhtrk%3D (Pubitemid 37168186)
33. JR Wingard HL Leather 2001 Empiric antifungal therapy for the neutropenic patient Oncology (Huntingt) 15 3 351 363 1:STN:280:DC%2BD3MvjsFanuw%3D%3D (Pubitemid 33739173)
34. AG Freifeld EJ Bow KA Sepkowitz, et al. 2011 Clinical practice guideline for the use of antimicrobial agents in neutropenic patients with cancer: 2010 update by the Infectious Diseases Society of America Clin Infect Dis 52 e56 e93 21258094 10.1093/cid/cir073
35. DW Kubiak JM Bryar AM McDonnell, et al. 2010 Evaluation of caspofungin or micafungin as empiric antifungal therapy in adult patients with persistent febrile neutropenia: a retrospective, observational, sequential cohort analysis Clin Ther 32 637 648 20435233 10.1016/j.clinthera.2010.04.005 1:CAS:528:DC%2BC3cXosVSnurY%3D
36. J Maertens K Theunissen G Verhoef, et al. 2005 Galactomannan computed tomography-based preemptive therapy in neutropenic patients at high risk for invasive fungal infection: a prospective feasibility study Clin Infect Dis 41 1242 1250 16206097 10.1086/496927 1:CAS:528:DC%2BD2MXht1WisbfE (Pubitemid 41534660)
37. C Cordonnier C Pautas S Maury, et al. 2009 Empirical versus preemptive antifungal therapy for high-risk febrile neutropenic patients: a randomized, controlled trial Clin Infect Dis 48 1042 1051 19281327 10.1086/597395 1:CAS:528:DC%2BD1MXltFektL4%3D
38. O Blennow M Remberger L Klingspor, et al. 2010 Randomized PCR-based therapy and risk factors for invasive fungal infection following reduced intensity conditioning and hematopoietic stem cell transplantation Bone Marrow Transplant 45 1710 1718 20190840 10.1038/bmt.2010.38 1:STN:280: DC%2BC3M%2Fislaquw%3D%3D This study outlines the potential for fungal DNA PCR technology in earlier diagnosis of IFD and targeting antifungal therapy
39. L Klingspor S Jalal 2006 Molecular detection and identification of Candida and Aspergillus spp. from clinical samples using real time PCR Clin Microbiol Infect 12 745 753 16842569 10.1111/j.1469-0691.2006.01498.x 1:CAS:528:DC%2BD28XosFamu7o%3D (Pubitemid 43983799)
40. NE Jordanides EK Allan LA Mclintock, et al. 2005 A prospective study of real-time panfungal PCR for the early diagnosis of invasive fungal infection in heamto-oncology patients Bone Marrow Transplant 35 389 395 15640828 10.1038/sj.bmt.1704768 1:CAS:528:DC%2BD2MXhtFWns74%3D This study outlines the potential for fungal DNA PCR technology in earlier diagnosis of IFD (Pubitemid 40309485)
41. Robenshtok E, Gafter-Gvilli A, Goldberg E et al. Antifungal prophylaxis in cancer patients after chemotherapy or hematopoietic stem-cell transplantation: systematic review and meta-analysis. J Clin Oncol. 2007;25:5471-89. (Pubitemid 350232225)
42. Tomblyn M, Chiller T, Einsele H, et al. Guidelines for preventing infectious complications among hematopoietic cell transplant recipients: a global perspective. Biol Blood Marrow Transplant. 2009;15(10):1143-1238.36.
43. KA Marr 2001 Antifungal prophylaxis in hematopoietic stem cell transplant recipients Curr Opin Infect Dis 14 423 426 11964859 10.1097/00001432-200108000- 00004 1:CAS:528:DC%2BD38Xht1yntbo%3D (Pubitemid 32675487)
44. JR Wingard SL Carter TJ Walsh, et al. 2010 Randomized, double-blind trial of fluconazole versus voriconazole for prevention of invasive fungal infection after allogeneic hematopoietic cell transplantation Blood 116 5111 5118 20826719 10.1182/blood-2010-02-268151 1:CAS:528:DC%2BC3MXotFU%3D This study outlines use of fungal free survival as the primary endpoint and informative censoring
45. DP Kontoyiannis MS Lionakis RE Lewis, et al. 2005 Zygomycosis in a tertiary-care cancer center in the era of Aspergillus-active antifungal therapy: a case control observational study of 27 recent cases J Infect Dis 191 135 1360 10.1086/428780
46. JR Wingard 2004 Design issues in a prospective randomized double-blinded trial of prophylaxis of fluconazole versus voriconazole after allogeneic hematopoietic cell transplantation Clin Infect Dis 39 S176 S180 15546114 10.1086/421953 (Pubitemid 40169343)
47. KA Marr F Crippa W Leisenring, et al. 2004 Itraconazole versus fluconazole for prevention of fungal infections in patients receiving allogeneic stem cell transplants Blood 103 1527 1533 14525770 10.1182/blood-2003-08-2644 1:CAS:528:DC%2BD2cXhsVSlu7k%3D (Pubitemid 38168674)
48. JL Goodman DJ Winston RA Greenfield, et al. 1992 A controlled trial of fluconazole to prevent fungal infections in patients undergoing bone marrow transplantation New Engl J Med 326 845 851 1542320 10.1056/NEJM199203263261301 1:STN:280:DyaK387nvVaqtw%3D%3D
49. JA van Burik V Ratanatharathorn DE Stepan, et al. 2004 Micafungin versus fluconazole for prophylaxis against invasive fungal infections during neutropenia in patients undergoing hematopoietic stem cell transplantation Clin Infect Dis 39 1407 1416 15546073 10.1086/422312 (Pubitemid 39518200)
50. I Sanchez-Ortega B Patino M Arnan, et al. 2011 Clinical efficacy and safety of primary antifungal prophylaxis with posaconazole versus itraconazole in allogeneic blood and marrow transplantation Bone Marrow Transplant 46 733 739 20697369 10.1038/bmt.2010.185 1:CAS:528:DC%2BC3MXlvFGnurg%3D
51. Marks DI, Kibbler C, Pagliuca A, et al. Voriconazole (VOR) vs itraconazole (ITR) for primary prophylaxis of invasive fungal infection (IFI) in allogeneic hematopoietic cell transplant (HCT) recipients [abstract M-1249a]. In: Program and abstracts of the 49th Interscience Conference on Antimicrobial Agents and Chemotherapy, San Francisco, CA, 2009.
52. AJ Ulmann JH Lipton DH Vesole, et al. 2007 Posaconazole or fluconazole for prophylaxis in severe graft versus host disease New Engl J Med 356 335 347 10.1056/NEJMoa061098 (Pubitemid 46148776)
53. OA Cornely J Maertens DJ Winston, et al. 2007 Posaconazole versus fluconazole or itraconazole prophylaxis in patients with neutropenia New Engl J Med 356 348 359 17251531 10.1056/NEJMoa061094 1:CAS:528:DC%2BD2sXhtVGrsrw%3D (Pubitemid 46148777)
54. J Maertens K Buve K Theunissen, et al. 2009 Galactomannan serves as a surrogate endpoint for outcome of pulmonary invasive aspergillosis in neutropenic hematology patients Cancer 115 355 362 19117035 10.1002/cncr.24022
55. CD Pfeiffer JP Fine N Safdar 2006 Diagnosis of invasive aspergillosis using a galactomannan assay: a meta-analysis Clin Infect Dis 42 1417 1427 16619154 10.1086/503427 1:CAS:528:DC%2BD28Xlt1Cqu74%3D
56. A Hot C Maunoury S Poiree, et al. 2011 Diagnostic contribution of positron emission tomography with [18F]fluorodeoxyglucose for invasive fungal infections Clin Microbiol Infect 17 409 417 20636432 10.1111/j.1469-0691.2010. 03301.x 1:STN:280:DC%2BC3M3lvFSjtA%3D%3D FDG-PET role in the earlier diagnosis and treatment of IFD as well as in assessing outcomes and determining the optimal duration of antifungal therapy is discussed
57. KE Harda M Yigala I Arivi, et al. 2009 Impact of PCR-based diagnosis of invasive pulmonary aspergillosis on clinical outcome Bone Marrow Transplant 44 595 599 10.1038/bmt.2009.65 Fungal DNA PCR role in the earlier diagnosis and treatment of IFD as well as in assessing outcomes and determining the optimal duration of antifungal therapy is analyzed